| Name | Title | Contact Details |
|---|
Simplex Diabetic Supply Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Brentwood, TN. To find more information about Simplex Diabetic Supply Inc., please visit www.simplexdiabetes.com
APAC Pharmaceutical is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
QualCare, Inc., one of the region`s leading providers of health care coverage, provides the public and private marketplace with a higher-quality, lower-cost alternative to commercial insurance companies. QualCare`s network covers over 100 acute, specialty and rehabilitation hospitals, as well as over 31,000 physicians and other ancillary providers across New Jersey, New York and Pennsylvania. Founded in 1991 from a consortium of hospital systems, QualCare has experienced dramatic growth over the past two decades. Currently, 16 of New Jersey`s largest and most successful hospitals own and serve on QualCare`s Board of Directors. QualCare services over 900,000 members, with a clientele that spans health systems, unions, local governments, school boards, small to large businesses and some of New Jersey`s largest corporations. With rate increases that are consistently below industry standards and unparalleled service satisfaction, QualCare is well positioned to succeed in the changing healthcare industry.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
Pace Organization Of Rhode Island is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.